



## Announcement Summary

---

**Entity name**

PRESCIENT THERAPEUTICS LIMITED

**Announcement Type**

New announcement

**Date of this announcement**

Monday July 27, 2020

**The Proposed issue is:**

An offer of securities under a securities purchase plan

**Total number of +securities proposed to be issued for an offer of securities under a securities purchase plan**

ASX +security code	+Security description	Maximum Number of +securities to be issued
PTX	ORDINARY FULLY PAID	118,181,818

**+Record date**

Friday July 24, 2020

**Offer closing date**

Monday August 17, 2020

**+Issue date**

Monday August 24, 2020

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

---

**1.1 Name of +Entity**

PRESCIENT THERAPEUTICS LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

**1.2 Registered Number Type**

ABN

**Registration Number**

56006569106

**1.3 ASX issuer code**

PTX

**1.4 The announcement is**

New announcement

**1.5 Date of this announcement**

Monday July 27, 2020

**1.6 The Proposed issue is:**

An offer of +securities under a +securities purchase plan



Part 4 - Details of proposed offer under securities purchase plan

---

Part 4A - Conditions

---

**4A.1 - Are any of the following approvals required for the offer of +securities under the +securities purchase plan issue to be unconditional?**

- +Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- Another approval/condition external to the entity

No

Part 4B - Offer details

---

**Class or classes of +securities that will participate in the proposed issue and class or classes of +securities proposed to be issued**

**ASX +security code and description**

PTX : ORDINARY FULLY PAID

**Will the proposed issue of this +security include an offer of attaching +securities?**

No

Details of +securities proposed to be issued

---

**ASX +security code and description**

PTX : ORDINARY FULLY PAID

**Maximum total number of those +securities that could be issued if all offers under the +securities purchase plan are accepted**

118,181,818

**Will the offer be conditional on applications for a minimum number of +securities being received or a minimum amount being raised (i.e. a minimum subscription condition)?**

No

**Will the offer be conditional on applications for a maximum number of +securities being received or a maximum amount being raised (i.e. a maximum subscription condition)?**

No



**Will individual security holders be required to accept the offer for a minimum number or value of +securities (i.e. a minimum acceptance condition)?**

Yes

**Is the minimum acceptance unit based or dollar based?**

Dollar based (\$)

**Please enter the minimum acceptance value**

\$ 5,000

**Will individual security holders be limited to accepting the offer for a maximum number or value of +securities (i.e. a maximum acceptance condition)?**

Yes

**Is the maximum acceptance unit based or dollar based?**

Dollar based (\$)

**Please enter the maximum acceptance value**

\$ 30,000

**Describe all the applicable parcels available for this offer in number of securities or dollar value**

\$5,000 for 90,910 shares, \$10,000 for 181,819 shares, \$15,000 for 272,728 shares, \$20,000 for 363,637 shares, \$25,000 for 454,546 shares, \$30,000 for 545,455 shares

**Offer price details**

**Has the offer price been determined?**

Yes

**In what currency will the offer be made?**

AUD - Australian Dollar

**What is the offer price per +security?**

AUD 0.05500

**Oversubscription & Scale back details**

**Will a scale back be applied if the offer is over-subscribed?**

Yes

**Describe the scale back arrangements**

If Applications are scaled back, the share allocation of Eligible Shareholders participating in the SPP will be reduced on a pro rata basis based on the size of the existing security holding of the Eligible Shareholder as at the Record Date

**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?**

Yes



**4C.1 Date of announcement of +security purchase plan**

Monday July 27, 2020

**4C.2 +Record date**

Friday July 24, 2020

**4C.3 Date on which offer documents will be made available to investors**

Monday July 27, 2020

**4C.4 Offer open date**

Tuesday July 28, 2020

**4C.5 Offer closing date**

Monday August 17, 2020

**4C.6 Announcement of results**

Thursday August 20, 2020

**4C.7 +Issue date**

Monday August 24, 2020

Part 4D - Listing Rule requirements

---

**4D.1 Does the offer under the +securities purchase plan meet all of the requirements of listing rule 7.2 exception 5 or do you have a waiver from those requirements?**

Yes

Part 4E - Fees and expenses

---

**4E.1 Will there be a lead manager or broker to the proposed offer?**

No

**4E.2 Is the proposed offer to be underwritten?**

Yes

**4E.2a Who are the underwriter(s)?**

Viriathus Capital Pty Ltd ACN 113 959 596

**4E.2b What is the extent of the underwriting (ie the amount or proportion of the issue that is underwritten)?**

\$4,000,000



**4E.2c What fee, commission or other consideration is payable to them for acting as underwriter(s)?**

- an underwriting fee of 3.5% of the Underwritten Amount; and
- a placement fee of 3.5% of any part of the Underwritten Amount which is paid by the Underwriter to the Company; and
- the Underwriter's reasonable costs and expenses up to a limit of \$1,000 unless otherwise approved by the Company,

**4E.2d Please provide a summary of the significant events that could lead to the underwriting being terminated.**

- The key terms are summarised in the offer booklet in section 4 but summarised below:
- (a) a statements in the offer document or cleansing statement is inaccurate or misleading;
  - (b) drops in the market by 10% or more below the level on the business day before the date the Offer is announced (details within offer document);
  - (c) regulatory investigations in relation to the offers;
  - (d) removal from ASX Listing;
  - (e) a director or a senior manager of a Relevant Company is charged with an indictable offence;
  - (f) insolvency;
  - (g) changes to the timetable greater than three days without prior written consent;
  - (h) changes to the capital structure; and
  - (i) other items as outlined within the offer booklet.

**4E.2e Is a party referred to in listing rule 10.11 underwriting or sub-underwriting the proposed offer?**

No

**4E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission?**

No

**4E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer**

Part 4F - Further Information

---

**4F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue**

The funds raised from the SPP will be used to progress the Company's clinical and pre-clinical programs in both targeted cellular therapies for the development of personalised cancer approaches; general working capital and costs of the offer.

**4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful?**

No

**4F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer**

All Countries outside Australia and New Zealand

**4F.3 URL on the entity's website where investors can download information about the proposed offer**

<https://prescienttherapeutics.investorportal.com.au/>

**4F.4 Any other information the entity wishes to provide about the proposed offer**

